Xponance Inc. Sells 263 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Xponance Inc. lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 2,798 shares of the medical research company’s stock after selling 263 shares during the quarter. Xponance Inc.’s holdings in Bio-Rad Laboratories were worth $764,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Brio Consultants LLC purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at $840,000. Corient Private Wealth LLC raised its stake in Bio-Rad Laboratories by 11.2% in the fourth quarter. Corient Private Wealth LLC now owns 2,178 shares of the medical research company’s stock worth $703,000 after buying an additional 220 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in Bio-Rad Laboratories by 34.3% in the fourth quarter. Hsbc Holdings PLC now owns 29,067 shares of the medical research company’s stock worth $9,401,000 after buying an additional 7,426 shares during the period. Parallel Advisors LLC boosted its position in Bio-Rad Laboratories by 36.8% during the 4th quarter. Parallel Advisors LLC now owns 171 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 46 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of Bio-Rad Laboratories by 8.5% during the 4th quarter. TD Asset Management Inc now owns 5,505 shares of the medical research company’s stock worth $1,778,000 after acquiring an additional 431 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.1 %

NYSE BIO opened at $331.77 on Monday. Bio-Rad Laboratories, Inc. has a 12 month low of $261.59 and a 12 month high of $366.30. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock’s fifty day moving average price is $325.80 and its 200-day moving average price is $307.02. The stock has a market cap of $9.46 billion, a P/E ratio of -32.02 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, beating the consensus estimate of $2.12 by $0.99. The company had revenue of $638.50 million for the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. Bio-Rad Laboratories’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.00 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Insider Activity at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $401.00 target price on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Jefferies Financial Group reissued a “hold” rating and set a $315.00 price objective (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price on the stock. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Citigroup upped their price objective on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $358.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.